Proton beam plus immunotherapy shows promise against hard-to-treat liver cancer
NCT ID NCT06133062
First seen Apr 01, 2026 · Last updated May 01, 2026 · Updated 6 times
Summary
This study tests whether adding proton radiation to standard immunotherapy (atezolizumab and bevacizumab) can improve outcomes for people with liver cancer that cannot be removed by surgery. About 45 participants will receive the combination therapy. The goal is to see if this approach shrinks tumors, delays cancer growth, and activates the immune system against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung Memorial Hospital at Linkou
RECRUITINGTaoyuan City, Taiwan, 333, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.